Amgen slips after late-stage trial data for Sjögren's disease therapy

What happened

Amgen shares fell in premarket trading Wednesday after the company released detailed results from its Phase 3 OASIZ 301 trial of experimental Sjögren's disease therapy dazodalibep. The 48-week results showed reductions in disease activity scores at both tested doses, while the 1,500 mg dose also improved patient-reported dryness.

Confirmed

Global impact / market context

The results add clinical evidence for dazodalibep, but the therapy remains experimental, so they do not establish that it will reach patients or generate sales. If development succeeds, approval and adoption could create a new revenue source for Amgen; further trial and regulatory steps remain important.

Analyst inference

The reported share decline followed the data release, although the article gives no reason for the move. The findings are potentially relevant to Amgen's future drug pipeline, but one trial presentation does not show likely commercial demand, pricing, costs, or the therapy's contribution to company earnings.

Analyst inference

What to watch

1. Watch for Amgen's next stated development steps for dazodalibep; continued testing would provide more evidence about whether the observed benefits are consistent and clinically meaningful. Analyst inference
2. Look for further trial results on patient-reported dryness and disease activity, including whether improvements persist and whether safety information is reported alongside the benefits. Analyst inference
3. Follow any regulatory updates on dazodalibep; approval decisions determine whether an experimental therapy can be sold, while the article reports no approval or filing. Analyst inference

Evidence

• seekingalpha.com